Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
Titel:
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
Auteur:
Stintzing, S. Miller-Phillips, L. Modest, D.P. Fischer von Weikersthal, L. Decker, T. Kiani, A. Vehling-Kaiser, U. Al-Batran, S.-E. Heintges, T. Kahl, C. Seipelt, G. Kullmann, F. Stauch, M. Scheithauer, W. Held, S. Moehler, M. Jagenburg, A. Kirchner, T. Jung, A. Heinemann, V.